Corsair Capital Management L.P. Acquires Shares of 24,370 MEI Pharma, Inc. (NASDAQ:MEIP)

Corsair Capital Management L.P. bought a new position in shares of MEI Pharma, Inc. (NASDAQ:MEIP) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 24,370 shares of the company’s stock, valued at approximately $69,000. Corsair Capital Management L.P. owned about 0.37% of MEI Pharma at the end of the most recent reporting period.

Separately, National Bank of Canada FI lifted its position in MEI Pharma by 43.5% during the second quarter. National Bank of Canada FI now owns 33,000 shares of the company’s stock worth $94,000 after buying an additional 10,000 shares in the last quarter. 52.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on MEI Pharma in a report on Saturday. They set a “buy” rating on the stock. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

MEI Pharma Stock Up 2.9 %

Shares of MEI Pharma stock opened at $2.84 on Wednesday. The business’s fifty day simple moving average is $2.89 and its 200-day simple moving average is $3.01. MEI Pharma, Inc. has a 52 week low of $2.61 and a 52 week high of $6.91.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) EPS for the quarter. As a group, sell-side analysts expect that MEI Pharma, Inc. will post -5.1 EPS for the current year.

MEI Pharma Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.